Vaccine prevention of acute otitis media

Current Allergy and Asthma Reports

Volumn 1, Issue 4, 2001, Pages 358-363

  Greenberg, David P ^a   Hoberman, Alejandro ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Acute Otitis Medium; Influenza; Influenza Vaccine; Moraxella Catarrhalis; Respiratory Syncytial Virus

Indexed keywords

BACTERIAL PROTEIN; OUTER MEMBRANE PROTEIN; PNEUMOCOCCUS VACCINE; INFLUENZA VACCINE;

ACUTE OTITIS MEDIA; ARTICLE; DISEASE ASSOCIATION; FIMBRIA; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION PREVENTION; MORAXELLA CATARRHALIS; NONHUMAN; PARAINFLUENZA VIRUS INFECTION; PATHOGENESIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEASONAL INFLUENZA; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; ACUTE DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; FINLAND; INFANT; MICROBIOLOGY; OTITIS MEDIA; PRESCHOOL CHILD; UNITED STATES;

ACUTE DISEASE; CHILD, PRESCHOOL; CLINICAL TRIALS; FINLAND; HUMANS; INCIDENCE; INFANT; INFLUENZA VACCINES; OTITIS MEDIA; PNEUMOCOCCAL VACCINES; UNITED STATES; VACCINATION;

EID: 0035412238     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-001-0049-8     Document Type: Article

References (49)

1. Freid VM, Makuc DM, Rooks RN: Ambulatory health care visits by children: principal diagnosis and place of visit. Hyattsville: Centers for Disease Control and Prevention/National Center for Health Statistics; 1998. [Vital and Health Statistics 13:1-23.]
2. Schappert SM: Office visits for otitis media: United States, 1975–90. Hyattsville: Centers for Disease Control and Prevention/National Center for Health Statistics; 1992. [Vital and Health Statistics Adv Data 214:1-18.]
3. Daly KA, Hunter LL, Giebink GS: Chronic otitis media with effusion. Pediatr Rev 1999, 20:85–93.
4. Gates GA: Cost-effectiveness considerations in otitis media treatment. Otolaryngol Head Neck Surg 1996, 114:525–530.
5. Paradise JL, Rockette HE, Colborn K, et al.: Otitis media in 2253 Pittsburgh-area infants: prevalence and risk factors during the first two years of life. Pediatrics 1997, 99:318–333.
6. Teele DW, Klein JO, Rosner B: Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989, 160:83–94.
7. Lim DJ, Chun YM, Lee HY, et al.: Cell biology of tubotympanum in relation to pathogenesis of otitis media - a review. Vaccine 2001, 19:S17-S25.
8. Rynnel-Dagoo B, Agren K: The nasopharynx and the middle ear: inflammatory reactions in middle ear disease. Vaccine 2001, 19:S26-S31.
9. Giebink GS, Ripley ML, Wright PF: Eustachian tube histopathology during experimental influenza A virus infection in the chinchilla. Ann Otol Rhinol Laryngol 1987, 96:199–206.
10. Sanyal MA, Henderson FW, Stempel EC, et al.: Effect of upper respiratory tract infection on eustachian tube ventilatory function in the preschool child. J Pediatr 1980, 97:11–15.
11. Heikkinen T: Role of viruses in the pathogenesis of acute otitis media. Pediatr Infect Dis J 2000, 19:S17-S23.
12. Heikkinen T, Ruuskanen O: Temporal development of acute otitis media during upper respiratory tract infection. Pediatr Infect Dis J 1994, 13:659–661.
13. Ruuskanen O, Arola M, Putto-Laurila A, et al.: Acute otitis media and respiratory virus infections. Pediatr Infect Dis J 1989, 8:94–99.
14. Heikkinen T, Thint M, Chonmaitree T: Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 1999, 340:260–264. Using culture and antigen detection techniques, the investigators found RSV in the middle ear fluid of 74% of children in whom the same virus was found in nasopharyngeal secretions, PIV in 52%, and influenza virus in 42%.
15. Pitkaranta A, Virolainen A, Jero J, et al.: Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics 1998, 102:291–295. These investigators used RT-PCR to detect rhinovirus RNA in the middle ear fluid of 64% of children with the same virus in their nasopharyngeal secretions, RSV in 57%, and coronavirus in 36%.
16. Heikkinen T, Ruuskanen O, Waris M, et al.: Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child 1991, 145:445–448.
17. Clements DA, Langdon L, Bland C, Emmanuel W: Influenza A vaccine decreases incidence of otitis media in 6- to 30- month-old children in day care. Arch Pediatr Adolesc Med 1995, 149:1113–1117.
18. Belshe RB, Mendelman PM, Treanor J, et al.: The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998, 338:1405–1412. A novel trivalent, live attenuated, intranasal influenza vaccine was 93% efficacious against culture-positive influenza and resulted in 30% fewer episodes of febrile AOM.
19. Hoberman A, Greenberg DP, Paradise JL, et al.: Efficacy of influenza vaccine in the prevention of acute otitis media (AOM) [abstract]. Pediatr Res 2001, in press.
20. Simoes EAF, Groothuis JR, Tristram DA, et al.: Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J Pediatr 1996, 129:214–219.
21. Karron RA, Wright PF, Crowe JE Jr, et al.: Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997, 176:1428–1436.
22. Wright PF, Karron RA, Crowe JE Jr, et al.: Evaluation of a live, attenuated respiratory syncytial virus (RSV) vaccine candidate, cpts 248/404, in infancy. Pediatr Res 1998, 43:161A.
23. Collins PL, Whitehead SS, Bukreyev A, et al.: Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res 1999, 54:423–451.
24. Tristram DA, Welliver RC, Mohar CK, et al.: Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18–36 months old. J Infect Dis 1993, 167:191–195.
25. Belshe RB, Anderson EL, Walsh EE: Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 1993, 168:1024–1029.
26. Groothuis JR, King SJ, Hogerman DA, et al.: Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronochopulmonary dysplasia. J Infect Dis 1998, 177:467–469.
27. Piedra PA, Grace S, Jewell A, et al.: Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 1996, 15:23–31.
28. Falsey AR, Walsh EE: Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997, 15:1130–1132.
29. Belshe RB, Karron RA, Newman FK, et al.: Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children. J Clin Microbiol 1992, 30:2064–2070.
30. Karron RA, Wright PF, Newman FK, et al.: A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 1995, 172:1445–1450.
31. Karron RA, Wright PF, Hall SL, et al.: A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic and phenotypically stable in infants and children. J Infect Dis 1995, 171:1107–1114.
32. Karron RA, Makhene M, Gay K, et al.: Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J 1996, 15:650–654.
33. Greenberg DP, Yeh S, Yogev R, et al.: Evaluation of the safety, immunogenicity and virus shedding of an intranasal live attenuated bovine parainfluenza virus type 3 vaccine in infants. Pediatr Res 1999, 45:161A.
34. American Academy of Pediatrics: Recommended childhood immunization schedule—United States, January-December 2001. Pediatrics 2001, 107:202.
35. Zenni MK, Cheatham SH, Thompson JM, et al.: Streptococcus pneumoniae colonization in the young child: association with otitis media and resistance to penicillin. J Pediatr 1995, 127:533–537.
36. Dagan R, Muallem M, Melamed R, et al.: Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997, 16:1060–1064.
37. Black S, Shinefield H, Fireman B, et al.: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000, 19:187–195. In this double-blind, randomized, placebo-controlled trial of 37,868 children, heptavalent PCV was 93.9% efficacious against invasive pneumococcal infections caused by vaccine serotypes. The vaccine reduced the incidence of all episodes of AOM by 6.4%, visits for AOM by 7.8%, and the need for ventilatory tube placement by 20.3%.
38. Eskola J, Kilpi T, Palmu A, et al.: Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344:403–409. In this double-blind, randomized, placebo-controlled trial of 1662 children, heptavalent PCV reduced the incidence of all causes of AOM by 6%, all pneumococcal AOM by 34%, and AOM caused by vaccine serotypes by 57%.
39. Mbelle N, Huebner RE, Wasas AD, et al.: Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999, 180:1171–1176.
40. Briles DE, Hollingshead SK, Nabors GS, et al.: The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 2001, 19:S87-S95.
41. White P, Hermansson A, Svanborg C, et al.: Effects of active immunization with a pneumococcal surface protein (PspA) and of locally applied antibodies in experimental otitis media. ORL J Otorhinolaryngol Relat Spec 1999, 61:206–211.
42. Nabors GS, Braun PA, Herrmann DJ, et al.: Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly crossreactive antibodies to heterologous PspA molecules. Vaccine 2000, 18:1743–1754.
43. Foxwell RA, Kyd JM, Cripps AW: Nontypeable Haemophilus influenzae: pathogenesis and prevention. Microbiol Mol Biol Rev 1998, 62:294–308.
44. Kyd JM, Dunkley ML, Cripps AW: Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect Immun 1995, 63:2931–2940.
45. Yamanaka N, Faden H: Antibody response to outer membrane protein of nontypeable Haemophilus influenzae in otitisprone children. J Pediatr 1993, 122:212–218.
46. Bakaletz LO, Kennedy BJ, Novotny LA, et al.: Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Infect Immun 1999, 67:2746–2762.
47. Giebink GS: Vaccination against middle-ear bacterial and viral pathogens. Ann N Y Acad Sci 1997, 830:330–352.
48. Kyd J, John A, Cripps A, Murphy TF: Investigation of mucosal immunisation in pulmonary clearance of Moraxella (Branhamella) catarrhalis. Vaccine 2000, 18:398–406.
49. McMichael JC: Vaccines for Moraxella catarrhalis. Vaccine 2001, 19:S101-S107.